Results 121 to 130 of about 7,834 (208)

885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab

Regular and Young Investigator Award Abstracts, 2023
Edward T Richardson, Geoffrey I Shapiro, Jennifer L Guerriero, Claudine Isaacs, Filipa Lynce, Madeline G Townsend, Kelly F Zheng, Paula R Pohlmann, Kenichi Shimada, Arielle Heeke, Xue Geng, Candace Mainor, Mei Wei, Julie M Collins, Lauren M Sloat, Jane Staunton, Stuart J Schnitt, Joan S Brugge, Hongkun Wang   +18 more
openaire   +2 more sources

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends

Cancer Management and Research
Bicky Thapa,1,* Navonil De Sarkar,2– 4,* Subhajit Giri,2,3 Komal Sharma,2– 4 Mingee Kim,5 Deepak Kilari1 1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 2Medical College of Wisconsin Cancer Center ...
Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D   +5 more
doaj  

Talazoparib Regimen [PDF]

, 2020
openaire   +1 more source

Talazoparib Tosylate [PDF]

, 2020
openaire   +1 more source

Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions

Journal of Translational Medicine
Background The introduction of antibody–drug conjugates represents a significant advancement in targeted therapy of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Andrea Ghelli Luserna di Rorà, Mouna Jandoubi, Antonella Padella, Anna Ferrari, Andrea Marranci, Cristina Mazzotti, Francesco Olimpico, Martina Ghetti, Lorenzo Ledda, Maria Teresa Bochicchio, Matteo Paganelli, Michele Zanoni, Alessandro Cafaro, Chiara Servili, Sara Galimberti, Michele Gottardi, Michela Rondoni, Mauro Endri, Daniela Onofrillo, Ernesta Audisio, Giovanni Marconi, Giorgia Simonetti, Giovanni Martinelli   +22 more
doaj   +1 more source

New treatment option for ovarian cancer: PARP inhibitors [PDF]

, 2016

core   +1 more source

A REVIEW ARTICLE ON TALAZOPARIB – ANTI CANCER DRUG

Talazoparib tosylate (BMN-673, Talzenna; Pfizer) is an oral poly [ADP-ribose] polymerase (PARP) inhibitor (PARPi) that has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of germline BRCA-mutated locally advanced or metastatic breast cancer (BC). In preclinical and clinical studies,
openaire   +1 more source

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion. [PDF]

Proc Natl Acad Sci U S A
Abdulkareem NM, Jiang Y, Qi Y, Liu X, Zhang X, Cai S, Shao J, Jeter-Jones S, Rinkenbaugh AL, Cheng CC, Hancock F, Schwartz J, Litton JK, Chang JT, Piwnica-Worms H.   +14 more
europepmc   +1 more source

Tracking DNA damage localization and chromatin remodeling in live cells using time-resolved quantitative analysis of DNA counterstains. [PDF]

Cell Mol Life Sci
Paternò G, Longo E, Lanzanò L.
europepmc   +1 more source

PARP1 trapping activates cGAS-STING pathway to induce immunogenic cell death in multiple myeloma. [PDF]

Cancer Cell Int
Juli G, Ronchetti D, Signorelli S, Squillacioti S, Polerà N, Maienza A, Vocaturo M, Galvano A, Taiana E, Tagliaferri P, Tassone P, Caracciolo D.   +11 more
europepmc   +1 more source